Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Douglas Hunt Biography and Net Worth

Insider of Puma Biotechnology

Mr. Hunt joined Puma Biotechnology as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management in January 2018. Mr. Hunt was Vice President of Regulatory Affairs and Quality Assurance at Armagen Inc, from April 2015 to December 2017, where he supported the continuing development of multiple products designed to cross the Blood Brain Barrier. He served as Vice President Global Regulatory Affairs for Baxter Healthcare from 2008 to 2015. During his tenure at Baxter he led a team responsible for gaining global approvals in various bleeding disorders, influenza and the treatment of various immune deficiencies. Notably, he supported the successful U.S. advisory Committee that supported the approval of HyQuvia. From March 2000 to July 2008, Mr. Hunt held various roles at Amgen, including Therapeutic Area lead in Inflammation and Oncology. During his tenure at Amgen, he supported the development and approval of Neulasta, Aranesp, Enbrel and NPlate. Prior to joining Amgen, Mr. Hunt worked for Quintiles, providing regulatory support to multiple development programs.

Mr. Hunt received a B.Sc from the University of Portsmouth (UK). He is a Fellow of the Regulatory Affairs Professionals Society.

What is Douglas M. Hunt's net worth?: The estimated net worth of Douglas M. Hunt is at least $215,851.36 as of November 2nd, 2022. Mr. Hunt owns 76,004 shares of Puma Biotechnology stock worth more than $215,851 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Hunt may own. Additionally, Mr. Hunt receives an annual salary of $598,000.00 as Insider at Puma Biotechnology. Learn More about Douglas M. Hunt's net worth.
How old is Douglas M. Hunt?: Mr. Hunt is currently 59 years old. There are 3 older executives and no younger executives at Puma Biotechnology. Learn More on Douglas M. Hunt's age.
What is Douglas M. Hunt's salary?: As the Insider of Puma Biotechnology, Inc., Mr. Hunt earns $598,000.00 per year. There are 3 executives that earn more than Mr. Hunt. The highest earning executive at Puma Biotechnology is Mr. Alan H. Auerbach, Founder, Chairman, President, CEO & Secretary, who commands a salary of $1,300,000.00 per year. Learn More on Douglas M. Hunt's salary.
How do I contact Douglas M. Hunt?: The corporate mailing address for Mr. Hunt and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Douglas M. Hunt's contact information.
Has Douglas M. Hunt been buying or selling shares of Puma Biotechnology?: Douglas M. Hunt has not been actively trading shares of Puma Biotechnology over the course of the past ninety days. Most recently, Douglas M. Hunt sold 429 shares of the business's stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $2.25, for a transaction totalling $965.25. Following the completion of the sale, the insider now directly owns 76,004 shares of the company's stock, valued at $171,009. Learn More on Douglas M. Hunt's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 174,074 shares worth more than $667,379.98. The most recent insider tranaction occured on August, 12th when Director Michael Patrick Miller sold 23,358 shares worth more than $81,519.42. Insiders at Puma Biotechnology own 23.7% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 8/12/2024.

Douglas M. Hunt Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/2/2022	Sell	429	$2.25	$965.25	76,004
10/3/2022	Sell	435	$2.34	$1,017.90	76,433
8/2/2022	Sell	429	$2.89	$1,239.81	77,301
7/5/2022	Sell	3,753	$2.63	$9,870.39	77,730
5/3/2022	Sell	438	$2.31	$1,011.78	81,900
3/2/2022	Sell	446	$2.26	$1,007.96
2/2/2022	Sell	533	$2.47	$1,316.51
1/3/2022	Sell	3,707	$3.21	$11,899.47
11/2/2021	Sell	427	$5.64	$2,408.28
10/4/2021	Sell	443	$6.15	$2,724.45
9/2/2021	Sell	422	$7.52	$3,173.44
8/2/2021	Sell	420	$7.53	$3,162.60	66,523
7/2/2021	Sell	1,016	$9.15	$9,296.40	66,943
6/2/2021	Sell	416	$10.77	$4,480.32	67,959
5/3/2021	Sell	417	$9.91	$4,132.47	68,375
4/5/2021	Sell	426	$9.80	$4,174.80	68,792
1/4/2021	Sell	6,463	$10.23	$66,116.49	50,295
2/27/2020	Sell	1,728	$10.25	$17,712.00	52,830
9/12/2019	Sell	1,711	$11.42	$19,539.62	14,400

Douglas M. Hunt Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $2.84

$2.66

$2.86

50 Day Range

MA: $2.75

$2.42

$3.30

2 Week Range

Now: $2.84

$2.22

$7.73

Volume

270,751 shs

Average Volume

565,949 shs

Market Capitalization

$139.42 million

P/E Ratio

5.92

Dividend Yield

N/A

Beta

1.09

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Douglas Hunt Biography and Net Worth

What is Douglas M. Hunt's net worth?

How old is Douglas M. Hunt?

What is Douglas M. Hunt's salary?

How do I contact Douglas M. Hunt?

Has Douglas M. Hunt been buying or selling shares of Puma Biotechnology?

Who are Puma Biotechnology's active insiders?

Are insiders buying or selling shares of Puma Biotechnology?